Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel therapeutic approaches beyond standard treatments. Nanovaccines are a revolutionary platform in cancer immunotherapy, providing improved antigen delivery, enhanced immune activation, and targeted tumor targeting. This review critically discusses the promise of nanovaccines in HCC therapy, specifically focusing on their ability to induce strong antitumor immune responses while avoiding systemic toxicity. Key nanoplatforms such as lipid-based nanoparticles, polymeric carriers, and dendrimers are explained in detail to describe their mechanisms for encapsulating adjuvants and tumor-associated antigens to enhance immunogenicity. Further, we explain underlying mechanisms of action such as antigen cross-presentation, T-cell activation, and regulating the tumor microenvironment for immune evasion in HCC. Possible future directions in preclinical and clinical research and issues involving large-scale manufacturing and deployment are discussed, including combinatorial approaches using immune checkpoint inhibitors. This paper emphasizes the potentially transformative role of nanovaccines in the therapeutic regimen of HCC. It offers critical feedback on how their efficacy, safety, and translatability can be maximized for designing the next generation of cancer immunotherapies.